Enrollment is underway in a pivotal Phase 2/3 clinical trial evaluating Athersys’ (NASDAQ:ATHX) MultiStem cell therapy in COVID-19 patients with acute respiratory distress syndrome.
Target enrollment is 400 subjects. The primary endpoint is the number of ventilator-free days through day 28 versus placebo.
https://seekingalpha.com/news/3569108-athersys-up-3-premarket-multistem-study-in-covidminus-19-advances
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.